A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).

Bruno Sangro,James J. Harding,Matthew S. Johnson,Daniel H. Palmer,Julien Edeline,Ghassan K. Abou-Alfa,Ann-Lii Cheng,Thomas Decaens,Anthony B. El-Khoueiry,Richard S. Finn,Peter R. Galle,Joong Won Park,Thomas Yau,D. Begic,Yun Shen,Jaclyn Neely,Ashwin Reddy Sama,Masatoshi Kudo

A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).

2021

Bruno Sangro
James J. Harding
Matthew S. Johnson
Daniel H. Palmer
Julien Edeline
Ghassan K. Abou-Alfa
Ann-Lii Cheng
Thomas Decaens
Anthony B. El-Khoueiry
Richard S. Finn
Peter R. Galle
Joong Won Park
Thomas Yau
D. Begic
Yun Shen
Jaclyn Neely
Ashwin Reddy Sama
Masatoshi Kudo

TPS349Background: TACE is the most widely used locoregional therapy recommended for patients with intermediate-stage HCC (Barcelona Clinic Liver Cancer stage B). Despite the significant tumor respo...

Keywords:

intermediate stage
Nivolumab
Medicine
Internal medicine
Placebo
Randomized controlled trial
double blind
Gastroenterology
Ipilimumab
in patient
Hepatocellular carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations